Loading stock data…
Altimmune (ALT)
$3.35-0.01 (-0.30%)
After Hours$3.32-0.03 (-0.90%)· Last close Sep 9
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Altimmune, Inc. in the Healthcare sector is trading at $3.35 with a market capitalization of $509M. Wall Street consensus targets $17.22 (9 analysts), implying a +414.1% move over the next 12 months. The stock is currently 48% below its 52-week high of $6.44, remaining 7.7% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +414.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $26,000↑ | $5,000 | $5,000 | $5,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.24M↑ | -$28.89M↓ | -$20.86M↑ | -$22.92M↓ | -$21.82M |
| Net Income | -$22.56M↑ | -$27.36M↓ | -$19.01M↑ | -$22.15M↓ | -$19.57M |
Peer Comparison
JNJUNHPFE
Fundamentals
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$508.55M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-32.07%
Volume
Today's trading volume
3.07M
Recent News
Altimmune’s (ALT) Three Liver Trials Move Forward At Once
On August 12, Altimmune (NASDAQ:ALT) reported second quarter results that read less like a routine earnings update and more like a status check on three separate diseases at the same time. The clinical-stage biopharmaceutical company disclosed a newly launched global Phase 3 trial in MASH, positive Phase 2 data in alcohol use disorder, and completed […]
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
KOD's Zenkuda advances toward regulatory submission as its pipeline gains momentum. Key clinical data is expected later in 2026.
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.